UroToday7h
SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of ...
UroToday7h
SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants
SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...
UroToday7h
SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis
The cohort had a median age of 65 years (IQR 53–68), with 74% male and 82% Caucasian. Of the total 808 gene panel, 15 genes were mutated by >5% in the entire cohort, with PBRM1, SETD2, KDM5C, TP53, ...
UroToday22h
SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial
Low grade non-muscle invasive bladder cancer (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening Negative voiding cytology for high ...
UroToday1d
SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...
UroToday1d
SES AUA 2025: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reversal Thermal Gel
Patients with low-grade upper tract urothelial carcinoma receiving primary treatment with 6 once-weekly pyelocalyceal doses ...
UroToday1d
SES AUA 2025: First-in-Human Study of TAR-210 Erdafitinib Intravesical System in Patients with NMIBC with Select FGFR Alterations
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...
UroToday1d
SES AUA 2025: Survival Outcomes of Radical Prostatectomy versus Dose-Escalated Radiation with ADT in Node-Positive Prostate Cancer
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Arjun Pon Avudaiappan discussing survival outcomes of radical prostatectomy versus dose-escalated radiation with ADT ...
UroToday1d
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.
UroToday1d
SES AUA 2025: Characterization of Race-Based Expression within the ERG+ Molecular Subtype in High Grade Prostate Cancer
ERG positivity, an early molecular alteration in prostate cancer development, exhibits differing prevalence between African American and White patients. Nevertheless, the extent of race-based ...
UroToday1d
SES AUA 2025: Omission of Pelvic Lymph Node Dissection: A PET/CT Supplemented Approach
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Abhi Moolupuri discussing a PET/CT supplemented approach to omission of pelvic lymph node dissection. The National ...
UroToday1d
SES AUA 2025: Assessing Hematuria Screening Disparities Using the All of Us Database
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Jonathan Ryan ...